Olema's OP-3136 KAT6 inhibitor shows promising Phase 1 data with good tolerability.

Olema Pharmaceuticals announced encouraging initial clinical data from Phase 1 testing of OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities and tumor shrinkage in two-thirds of patients. The positive safety and efficacy findings support continued development as monotherapy and in combinations, potentially validating the company's oncology pipeline.